Literature DB >> 7828374

Anti-microfilament IgG antibodies in normal adults and in patients with autoimmune diseases: immunofluorescence and immunoblotting analysis of 201 subjects reveals polyreactivity with microfilament-associated proteins.

D Girard1, J L Senécal.   

Abstract

We have investigated IgG antibodies to microfilament-associated proteins in sera from 29 normal controls and from 172 patients with autoimmune diseases such as rheumatoid arthritis (n = 45), systemic lupus erythematosus (n = 43), polymyositis/dermatomyositis (n = 36), systemic sclerosis (n = 35), and autoimmune chronic active hepatitis (CAH, n = 13). We observed, by indirect immunofluorescence, a staining pattern in which the fluorescence was continuously distributed along microfilaments by using several animal and human cell lines as substrate. Because no reactivity with individual bands or specific combinations of bands was observed by immunoblotting using different cell lines, we further characterized our sera by immunoblotting using a panel of the purified microfilament-associated proteins filamin, myosin, alpha-actinin, actin, tropomyosin, and myosin light chain. Results shows that normal as well as autoimmune sera are polyreactive with microfilament proteins. The specificity of reactivity against a particular microfilament-associated protein was demonstrated by inhibition experiments with the specific protein. No correlation was observed between immunoblot and immunofluorescence results. Of the 201 sera, 40 (20%), 42 (21%), 31 (15%), 26 (13%), 34 (17%), 24 (12%), 4 (2%), and 0 (0%) reacted, respectively, by immunoblotting with 0, 1, 2, 3, 4, 5, 6, or 7 of the microfilament-associated proteins. Furthermore, 57 different profiles of reactivity with the panel proteins were observed. All autoimmune CAH sera reacted with at least 3 proteins. This result was strikingly unique to this group. Anti-actin antibodies were as common in normal as in CAH sera. Anti-alpha-actinin antibodies were strikingly more frequent in CAH than in any group. We conclude that a remarkable diversity of anti-microfilament antibodies is present in normal as well as in autoimmune sera and that a continuous microfilament fluorescent pattern is not restricted simply to anti-actin antibodies. Furthermore, sera negative by immunofluorescence react with several miocrofilament-associated proteins by immunoblotting. Reactivity with multiple (> or = 3) microfilament-associated proteins including alpha-actinin distinguishes CAH sera from normal and other autoimmune sera.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828374     DOI: 10.1006/clin.1995.1028

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  5 in total

1.  Re: Whither smooth muscle antibodies in the third millennium?

Authors:  S J Katona; P C Cooper; M E Cramp; E R Kaminski
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

2.  IgG from patients with liver diseases inhibit mitochondrial respiration in permeabilized oxidative muscle cells: impaired function of intracellular energetic units?

Authors:  Lumme Kadaja; Kai E Kisand; Nadezhda Peet; Urmo Braun; Kaja Metsküla; Kaupo Teesalu; Riina Vibo; Kalle V Kisand; Raivo Uibo; Harald Jockusch; Enn K Seppet
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

3.  Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1.

Authors:  Paul Guéguen; Georgios Dalekos; Jean-Baptiste Nousbaum; Kalliopi Zachou; Chaim Putterman; Pierre Youinou; Yves Renaudineau
Journal:  J Clin Immunol       Date:  2006-09-26       Impact factor: 8.542

4.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

5.  Mactinin: a modulator of the monocyte response to inflammation.

Authors:  Sharon D Luikart; Hollis E Krug; Robert D Nelson; Timothy Hinkel; Peter Majeski; Pankaj Gupta; Maren L Mahowald; Theodore Oegema
Journal:  Arthritis Res Ther       Date:  2003-08-05       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.